The response of breast cancer to hormonal therapy is strongly influenced by the level of estrogen receptor (ER) expression in the tumor. Currently, measures of the ER content of the primary tumor are used for breast cancer treatment selection. This approach is limited by heterogeneity of ER expression within tumors and between tumor sites. Up to 50% of patients with ER-positive tumors fail to respond to hormonal therapy. Furthermore, almost all patients initially responding to a particular hormonal agent will eventually fail therapy; but we have little insight to the timing of this failure or the likelihood of responding to alternative hormonal agents. The overall goal of this project is to measure regional tumor ER content in vivo. We hypothesize that we can predict response to hormonal therapy by non-invasive assessment of tumor estrogen binding using PET imaging and [F18]-16 alpha-fluoroestradiol (FES). Initial studies aimed at formulating quantitative imaging protocols in a variety of breast cancer patients have been completed. We have tested methods of quantifying estrogen binding in tumors using FES and have found good correlation between measures of FES uptake and quantitative ER immunocytochemistry in preliminary patient studies. This methodology will be applied to three aims: (1) Validate the ability the FES to measure ER content in both primary and metastatic tumors compared against assay of biopsy specimens, (2) Measure the heterogeneity of ER expression in patients with large tumors and/or multiple lesions using FES imaging and test the ability of these measurements to predict early response to hormonal therapy, and (3) Monitor the degree of estrogen blockade and changes in receptor expression over the course of tamoxifen therapy to identify potential mechanisms of acquired resistance. In addition to patient studies, we will perform laboratory and animal studies of FES transport and uptake into tissue to refine our analysis of FES PET images. We will measure FES binding to sex steroid binding protein (SBP) and FES and metabolite uptake into ER- containing tissue. In summary, we will use PET estrogen receptor imaging to answer basic question regarding the biology of the ER in breast cancer. This will lead to significant improvements in the use of hormonal therapy in breast cancer, including better selection of patients for hormonal therapy and better decisions on when and how the change therapy in those patients who fail tamoxifen therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA042045-15
Application #
6437371
Study Section
Project Start
2001-03-01
Project End
2002-02-28
Budget Start
Budget End
Support Year
15
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Lindner, Jonathan R; Link, Jeanne (2018) Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging 11:e005355
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7
Kurland, Brenda F; Muzi, Mark; Peterson, Lanell M et al. (2016) Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med 57:226-30
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S

Showing the most recent 10 out of 196 publications